Yes, haloperidol can definitely cause uncontrollable shaking.
Haloperidol causes acute extrapyramidal syndromes including tremor, acute dystonia (involuntary motor spasms), akathisia (restlessness), and drug-induced Parkinsonism, which are well-documented neurologic adverse effects of this medication 1.
Types of Movement Disorders from Haloperidol
The "uncontrollable shaking" can manifest as several distinct syndromes:
Acute Dystonia
- Involuntary motor tics or spasms involving the face, neck, back, and limb muscles
- Typically occurs after the first few doses or after dose increases 1
- Can include oculogyric crisis (eye muscle spasms)
- Laryngeal dystonia is rare but life-threatening, presenting as choking, difficulty breathing, or stridor
Tremor
- Occurs in approximately 24-39% of patients on haloperidol 2
- Can be part of drug-induced Parkinsonism syndrome
- May present as minor tremors or more significant shaking 3
Akathisia
- Subjective feeling of restlessness with motor manifestations
- Occurs in 31.7% of haloperidol-treated patients 4
- Generally develops within the first few days of therapy
Tardive Dyskinesia (Late-Onset)
- Potentially irreversible involuntary movements that can develop with chronic use 5
- Characterized by rapid involuntary facial movements (blinking, grimacing, chewing, tongue movements)
- Can also affect extremities and trunk
- Risk increases with duration of treatment and cumulative dose
- Oral administration may produce more intense tardive dyskinesia than parenteral routes 6
Critical Clinical Considerations
The FDA drug label carries explicit warnings about these movement disorders 5. The label emphasizes that tardive dyskinesia may be irreversible and that the syndrome can develop even after relatively brief treatment periods at low doses.
Risk Factors
- Older age, especially elderly women have highest risk for tardive dyskinesia 5
- Higher doses carry greater risk of extrapyramidal symptoms 7
- Longer duration of treatment increases risk
- IV haloperidol carries FDA warnings due to deaths at high doses 1
Management Algorithm
If acute dystonia or severe tremor occurs:
- Administer anticholinergic agents (e.g., diphenhydramine, benztropine)
- Dystonia typically resolves within 1 hour with treatment 7
- Consider dose reduction or medication switch
If drug-induced Parkinsonism develops:
- Add anticholinergic agent
- Add dopaminergic agonist (e.g., amantadine)
- Decrease haloperidol dose or switch to atypical antipsychotic 1
- Early diagnosis and rapid withdrawal may improve possibility of complete recovery
If tardive dyskinesia appears:
- Drug discontinuation should be strongly considered 5
- No known effective treatment for established cases
- Syndrome may remit partially or completely if antipsychotic withdrawn
- Some patients may require continued treatment despite the syndrome
Important Pitfall
Haloperidol can also cause Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition characterized by hyperpyrexia, muscle rigidity (which could be mistaken for "shaking"), altered mental status, and autonomic instability 1, 5, 8. This requires immediate drug discontinuation and intensive medical management.
Comparative Safety Data
Recent evidence shows that ziprasidone has notably lower incidence of movement disorders compared to haloperidol 4, while midazolam carries significantly higher risk of adverse events overall (OR 5.25 compared to haloperidol) 9. When movement disorders are a concern, atypical antipsychotics may be preferable alternatives.
The evidence consistently demonstrates across multiple high-quality guidelines that extrapyramidal symptoms, including various forms of uncontrollable shaking, are well-established and common adverse effects of haloperidol therapy that require vigilant monitoring and prompt intervention.